A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis with and without Rivaroxaban

• Published in: Medical science monitor Vol. 28; p. e934341
• Main Authors: Wang, Zi-Yan, Wan, You-Dong, Liu, Xian-Zhi, Wang, Hao, Jiang, Guang-Yi, Yang, Bo
• Format: Journal Article
• Language: English
• Published: United States International Scientific Literature, Inc 10.02.2022
• Subjects: Brain Neoplasms - surgery; Clinical Research; Double-Blind Method; Factor Xa Inhibitors - therapeutic use; Glioma - surgery; Humans; Middle Aged; Postoperative Complications - prevention & control; Rivaroxaban - therapeutic use; Venous Thromboembolism - prevention & control
• ISSN: 1643-3750; 1234-1010; 1643-3750
• DOI: 10.12659/MSM.934341

BACKGROUND Venous thrombosis (VTE) is a common adverse event among inpatients, which can cause pulmonary embolism, and greatly increases mortality. The effects of rivaroxaban in patients undergoing brain glioma surgery have still not been explored. This single-center study of 94 patients undergoing surgery for cerebral glioma aimed to compare postoperative thromboprophylaxis with and without rivaroxaban. MATERIAL AND METHODS We designed a randomized, controlled, double-blind study to evaluate the effect of rivaroxaban on 94 patients undergoing brain glioma surgery. These patients were divided into a rivaroxaban group (administered at 10 mg per day from admission to discharge) and a placebo group. The primary study endpoint was incidence of VTE at discharge. The secondary endpoints included safety outcomes of major bleeding, allergy, or VTE-related death. RESULTS A total of 94 patients were enrolled in the study: 47 in the rivaroxaban group and 47 in the placebo group. Baseline characteristics of participants were well-matched in both groups. A significant reduction was found in the incidence of VTE in the rivaroxaban treatment group versus the placebo group (1/47 vs 10/47 patients, P=0.008). The rate of major bleeding events was quite low in both group (1/47 vs 1/47 patients). One patient in the placebo group died due to a pulmonary embolism and intractable concomitant underlying diseases. CONCLUSIONS Our results indicate that treatment with rivaroxaban is a safe and effective thromboprophylaxis treatment in patients undergoing surgery for malignant cerebral glioma.